The Boston Cancer Summit
Alexion Pharmaceuticals Headquarters

Luke Timmerman Seattle Cancer Summit 

We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment — these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to the Kilimanjaro Climb to Fight Cancer, a philanthropic campaign to support basic science research at Fred Hutch.

NOTE: Last year’s event sold out in advance, and space is limited. Buy your tickets early to save your seat.

Confirmed speakers:

  • David Schenkein, executive chairman, Agios Pharmaceuticals
  • Mary Lynne Hedley, co-founder and president, Tesaro
  • Cindy Perettie, CEO, Foundation Medicine
  • Sanjiv Patel, CEO, Relay Therapeutics
  • Garry Menzel, CEO, TCR2 Therapeutics*
  • Simba Gill, CEO, Evelo Biosciences*
  • Uciane Scarlett, associate, Atlas Venture*
  • Katrine Bosley, biotech entrepreneur*
  • Praveen Tipirneni, CEO, Morphic Therapeutic*
  • Zoe Barry, CEO, ZappRx*
  • Phil Rowlands, Head, Oncology Therapeutic Area Unit, Takeda Pharmaceuticals
  • Deborah Palestrant, partner, 5AM Ventures; Head, 4:59
  • Elliott Sigal, venture partner, NEA
  • Leigh Zawel, CSO, small molecules, Cullinan Oncology; executive partner, MPM
  • Art Krieg, co-founder and chief scientific officer, Checkmate Pharmaceuticals
  • Luke Timmerman, founder and editor, Timmerman Report*
  • Tariq Kassum, COO, Obsidian Therapeutics
  • Doug Cole, managing partner, Flagship Pioneering
  • Leora Schiff, principal, Altius Strategy Consulting
  • Jeff Berkowitz, CEO, Real Endpoints
  • Karen Akinsanya, chief biomedical scientist, Schrodinger
  • Deaidra Smith, Director of Portfolio Communications, Alexion Pharmaceuticals*
  • Richa Wilson, Genentech/Roche, digital partnerships
  • Simon Kennedy, CEO, TriAxia Health


  • Veracyte
  • Alexandria Real Estate Equities 
  • Takeda Pharmaceuticals
  • Foundation Medicine
  • Madryn Asset Management
  • Alexion

*Denotes Kilimanjaro climber

Time: 1:00 PM - 6:00 PM
121 Seaport Blvd.
Boston, MA 02210

If you'd like to attend this event you can purchase tickets online.

(ticket purchase required)
(ticket purchase required)

Return to Calendar